SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 15(d) of the Securities Exchange Act of 1934.
Date of Report (Date of earliest event reported): July 25, 1996
FOUNTAIN PHARMACEUTICALS, INC.
------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-18399 62-1386759
--------------- --------------------- ---------------------------
(State of Inc.) (Commission File No.) (IRS Employer I.D. Number)
Registrant's telephone number: (813) 548-0900
<PAGE>
Item 1. Changes in Control of Registrant
- ------- --------------------------------
None.
Item 2. Acquisition or Disposition of Assets
- ------- ------------------------------------
None.
Item 3. Bankruptcy or Receivership
- ------- --------------------------
The United States Bankruptcy Court, Middle District of Florida,
Tampa Division, has issued a final decree on July 25, 1996, relating
to the Company's Chapter 11 Reorganization proceedings, and as such,
the Court no longer has jurisdiction over matters in connection with
the bankruptcy.
Item 4. Changes in Registrant's Certifying Accountant
- ------- ---------------------------------------------
None.
Item 5. Other Events
- ------- ------------
None.
Item 6. Resignations of Registrant's Directors
- ------- --------------------------------------
None.
Item 7. Financial Statements and Exhibits
- ------- ---------------------------------
(a) Exhibits: None.
(b) Reports on Form 8-K: None.
<PAGE>
FOUNTAIN PHARMACEUTICALS, INC.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
FOUNTAIN PHARMACEUTICALS, INC.
Dated: October 24, 1996 /s/JOHN C. WALSH
---------------------------------
JOHN C. WALSH,
Chief Executive Officer
